Skip to content

Multigene Methylation Kit Based on Plasma Samples for Assisting in Gastric Cancer Diagnosis: A Multicenter Clinical Study

Multigene Methylation Kit Based on Plasma Samples for Assisting in Gastric Cancer Diagnosis: A Multicenter Clinical Study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400091637
Enrollment
Unknown
Registered
2024-10-31
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Interventions

Observation group:None

Sponsors

Zhujiang Hospital, Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.No prior history of tumors. 2.Age between 18 and 75 years. 3.Male or non-pregnant, non-lactating female. 4.Patients have not received radiotherapy or chemotherapy prior to surgery. 5.Can provide adequate and qualified blood samples. 6.Patient resources have signed informed consent. For the Gastric Cancer Group: 7.Preoperative endoscopic examination with pathological diagnosis of colorectal adenocarcinoma or high-grade adenoma. For the Control Group: 8.Some individuals have certain digestive tract symptoms, and doctors recommend endoscopic examination; endoscopic examination with pathological diagnosis of benign gastric diseases. 9.Some individuals are healthy with endoscopic examination showing no significant lesions. 10.Other confirmed tumors not related to gastric cancer, including colorectal cancer, liver cancer, esophageal cancer, bile duct cancer, pancreatic cancer, and common non-digestive tract tumors such as lung cancer, breast cancer, cervical cancer, thyroid cancer, etc.

Exclusion criteria

Exclusion criteria: 1.Patients who participated in other clinical trials within 30 days prior to enrollment. 2.Women who are pregnant or lactating. 3.History of tumors and corresponding tumor treatments. 4.Received blood transfusion within 30 days prior to blood draw. 5.History of organ, bone marrow, or stem cell transplants. 6.Individuals whose health condition is unsuitable for blood collection. 7.Patients with incomplete clinical data (including TNM staging, tumor volume, pathological classification, site of occurrence, vascular invasion, age, sex, invasion depth, degree of differentiation, alcohol history, smoking history, etc.). 8.Diseases deemed unsuitable for the study by other researchers.

Design outcomes

Primary

MeasureTime frame
Methylation level;

Countries

China

Contacts

Public ContactCui Chunhui

Zhujiang Hospital, Southern Medical University

drcuich@163.com+86 135 7054 1388

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026